Jasper End Period Cash Flow from 2010 to 2024

JSPRW Stock  USD 0.22  0.01  4.76%   
Jasper Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 56.8 M in 2024. During the period from 2010 to 2024, Jasper Therapeutics End Period Cash Flow regression line of quarterly data had mean square error of 306.5 T and geometric mean of  33,406,397. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
87.3 M
Current Value
56.8 M
Quarterly Volatility
21.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 11.2 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.1. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Jasper Therapeutics Correlation against competitors.
For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.

Latest Jasper Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Jasper Therapeutics over the last few years. It is Jasper Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jasper Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Jasper End Period Cash Flow Regression Statistics

Arithmetic Mean37,311,324
Geometric Mean33,406,397
Coefficient Of Variation57.68
Mean Deviation15,814,875
Median27,163,000
Standard Deviation21,521,306
Sample Variance463.2T
Range67.1M
R-Value0.62
Mean Square Error306.5T
R-Squared0.39
Significance0.01
Slope2,988,200
Total Sum of Squares6484.3T

Jasper End Period Cash Flow History

202456.8 M
202387.3 M
202238.7 M
202185 M
202020.2 M

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow87.3 M56.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.